Kris M - Search Results

1

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. Ranson M, et al. Among authors: kris m. J Clin Oncol. 2002 May 1;20(9):2240-50. doi: 10.1200/JCO.2002.10.112. J Clin Oncol. 2002. PMID: 11980995 Clinical Trial.

2

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Francis PA, et al. Among authors: kris mg. Lung Cancer. 1995 Apr;12 Suppl 1:S163-72. doi: 10.1016/0169-5002(95)00432-z. Lung Cancer. 1995. PMID: 7551925 Free article. Review.

3

Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.

Miller VA, Rigas JR, Pisters KM, Grant SC, Pfister DG, Heelan RT, Kris MG. Miller VA, et al. Among authors: kris mg. Am J Clin Oncol. 1995 Aug;18(4):303-6. doi: 10.1097/00000421-199508000-00007. Am J Clin Oncol. 1995. PMID: 7625371 Clinical Trial.

4

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT. Francis PA, et al. Among authors: kris mg. J Clin Oncol. 1994 Jun;12(6):1232-7. doi: 10.1200/JCO.1994.12.6.1232. J Clin Oncol. 1994. PMID: 7911159 Clinical Trial.

5

Modulation of all-trans retinoic acid pharmacokinetics by liarozole.

Miller VA, Rigas JR, Muindi JR, Tong WP, Venkatraman E, Kris MG, Warrell RP Jr. Miller VA, et al. Among authors: kris mg. Cancer Chemother Pharmacol. 1994;34(6):522-6. doi: 10.1007/BF00685665. Cancer Chemother Pharmacol. 1994. PMID: 7923564 Clinical Trial.

6

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP Jr. Miller VA, et al. Among authors: kris mg. J Clin Oncol. 1997 Feb;15(2):790-5. doi: 10.1200/JCO.1997.15.2.790. J Clin Oncol. 1997. PMID: 9053506 Clinical Trial.

7

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.

Miller VA, Rigas JR, Tong WP, Reid JR, Pisters KM, Grant SC, Heelan RT, Kris MG. Miller VA, et al. Among authors: kris mg. Cancer Chemother Pharmacol. 1997;40(5):415-8. doi: 10.1007/s002800050679. Cancer Chemother Pharmacol. 1997. PMID: 9272118 Clinical Trial.

8

The development of docetaxel (Taxotere) in non-small cell lung cancer.

Kris MG, Miller VA, Ng KK, Grant SC. Kris MG, et al. Semin Oncol. 1997 Aug;24(4 Suppl 14):S14-1-S14-4. Semin Oncol. 1997. PMID: 9335515 No abstract available.

9

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG. Miller VA, et al. Among authors: kris mg. Ann Oncol. 1997 Dec;8(12):1269-71. doi: 10.1023/a:1008219125746. Ann Oncol. 1997. PMID: 9496394 Free article. Clinical Trial.

10

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.

Kindler HL, Kris MG, Smith IE, Miller VA, Grant SC, Krebs JB, Ross GA, Slevin ML. Kindler HL, et al. Among authors: kris mg. Am J Clin Oncol. 1998 Oct;21(5):438-41. doi: 10.1097/00000421-199810000-00003. Am J Clin Oncol. 1998. PMID: 9781595 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

535 results

Search Page

Filters